Edgar Filing: Gould Kevin S - Form 4

Cauld Varia C

Form 4	7										
Check this be	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									Number: 3235-0287	
if no longer subject to Section 16. Form 4 or Form 5 obligations may continue <i>See</i> Instruction 1(b).	Filed purse e. Section 17(a) on	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								2005 average rs per 0.5	
(Print or Type Resp	ponses)										
1. Name and Address of Reporting Person <u>*</u> Gould Kevin S			2. Issuer Name and Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer			
			BIO-TECHNE Corp [TECH]					(Check all applicable)			
(Last) 2948 WAUNE	()	3. Date of Earliest Transaction (Month/Day/Year) 10/26/2017					Director 10% Owner Officer (give title Other (specify below) SVP Clinical Controls				
		4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
NEWBURY PA	ARK, CA 9132	0							More than One Re		
(City)	(State) (Z	Zip)	Table	I - Non-De	rivative S	ecurit	ties Aco	quired, Disposed o	f, or Beneficial	lly Owned	
	. Transaction Date Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) o of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock				,,		(2)		1,355 <u>(1)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Gould Kevin S - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of tiorDerivative Securities) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	<u>(2)</u>	10/26/2017		А	1,949		(3)	(3)	Common Stock	1,949
Stock Options (Right to buy)	\$ 125.05	10/26/2017		А	10,742		(3)	08/09/2024	Common Stock	10,742
Stock Options (Right to buy)	\$ 125.05	10/26/2017		А	14,323		<u>(4)</u>	08/09/2024	Common Stock	14,323
Restricted Stock Units	(2)						(5)	(5)	Common Stock	2,111
Stock Options (Right to Buy)	\$ 106.59						<u>(6)</u>	08/18/2023	Common Stock	17,371
Stock Options (Right to Buy)	\$ 106.59						(5)	08/18/2023	Common Stock	13,028
Stock Options (Right to Buy)	\$ 97.23						(7)	07/09/2022	Common Stock	50,000
Stock Options (Right to Buy)	\$ 97.23						(8)	07/09/2022	Common Stock	15,000
Stock Options (Right to Buy)	\$ 88.23						<u>(9)</u>	01/04/2023	Common Stock	10,000

Reporting Owners

Reporting Owner Name / Address

Relationships

Other

Gould Kevin S 2948 WAUNETA STREET NEWBURY PARK, CA 91320

SVP Clinical Controls

Signatures

/s/ Brenda S. Furlow, attorney in fact for Kevin Gould pursuant to Power of Attorney filed here with

**Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Director

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 834 shares of restricted stock units that vest on 7/9/18.
- (2) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (3) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (4) Vests 3,580 shares on 8/9/2018 and 3,581 shares each on 8/9/2019, 8/9/2020, 8/9/2021.
- (5) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (6) Vests 4,343 shares on each of 8/18/17, 8/18/18 and 8/18/19, and 4,342 shares on 8/18/20.
- (7) 50,000 common stock options vest if certain performance goals are achieved for the 12 months ending 05/31/18.
- (8) Vests as to 3,750 shares on each of 7/9/16, 7/9/17, 7/9/18 and 7/9/19.
- (9) Vests as to 2,500 shares on each of 01/04/17, 01/04/18, 01/04/19 and 01/04/20.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

10/30/2017

Date